1.
Antimicrob Agents Chemother
; 50(2): 762-4, 2006 Feb.
Article
de Anglais
| MEDLINE
| ID: mdl-16436740
RÉSUMÉ
A practical preclinical model for the hyperbilirubinemia produced by human immunodeficiency virus protease inhibitors has been developed. Indinavir and atazanavir produced significant hyperbilirubinemia, whereas amprenavir, the negative control, was indistinguishable from the ritonavir booster dose. This model was used to disqualify an exploratory protease inhibitor from development.